FDA — authorised 5 May 1987
- Marketing authorisation holder: ABRAXIS PHARM
- Status: approved
🇺🇸 Cupric Sulfate in United States
FDA authorised Cupric Sulfate on 5 May 1987
Marketing authorisations
FDA — authorised 2 July 2020
- Application: NDA209376
- Marketing authorisation holder: AM REGENT
- Local brand name: MULTRYS
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 19 August 2024
- Application: ANDA218745
- Marketing authorisation holder: APOTEX CORP
- Local brand name: CUPRIC SULFATE
- Indication: INJECTABLE — INJECTION
- Status: approved
Cupric Sulfate in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Cupric Sulfate approved in United States?
Yes. FDA authorised it on 5 May 1987; FDA authorised it on 2 July 2020; FDA authorised it on 19 August 2024.
Who is the marketing authorisation holder for Cupric Sulfate in United States?
ABRAXIS PHARM holds the US marketing authorisation.